Skip to Main Content

Paper Details

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.
Nat Commun
5
2023
ERBB2, ERBB2 alleles, ERBB2 hemideletions, HER2, HER2-, HER2-0, HER2-0 tumors, HER2-low, HER2-negative metastatic breast cancer, breast cancer, breast tumors, patients, tumors
Author NameAffiliation
Ana C Garrido-CastroDana-Farber Cancer Institute
Ana C Garrido-CastroHarvard Medical School
Ana C Garrido-CastroDana-Farber Brigham Cancer Center
Andrew D CherniackDana-Farber Cancer Institute
Andrew D CherniackBroad Institute of Harvard and MIT
Andrew D CherniackHarvard Medical School
Andrew D CherniackDana-Farber Cancer Institute
Andrew D CherniackHarvard Medical School
Andrew D CherniackBroad Institute of Harvard and MIT
Sara M TolaneyDana-Farber Cancer Institute
Sara M TolaneyDana-Farber Brigham Cancer Center
Sara M TolaneyHarvard Medical School
  • 1 - 12

Datasets

Release 1.2